Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONCUR Study
NCT07055581Phase 2Recruiting
- Start
- Feb 2026
- Primary completion
- Jul 2029
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in small cell lung cancer (SCLC). Started Feb 2026; status: recruiting.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07055581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07055581.